Aclaris Therapeutics/ACRS

$1.21

-3.35%
-
1D1W1MYTD1YMAX

About Aclaris Therapeutics

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a pipeline of drug candidates to address the needs of patients with immuno-inflammatory diseases. The Company has a multi-stage portfolio of drug candidates powered by a robust research and development (R&D) engine exploring protein kinase regulation. The Company operates through two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The contract research segment includes provision of laboratory services. The Company is also engaged in identifying and consummating transactions with third-party partners, to further develop, obtain marketing approval for and/or commercialize its novel drug candidates.
Ticker
ACRS
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology & Drugs
CEO
Neal Walker
Employees
105
Headquarters
Wayne, United States

ACRS Metrics

BasicAdvanced
$84.3M
Market cap
-
P/E ratio
-$1.67
EPS
0.23
Beta
-
Dividend rate

What the Analysts think about ACRS

Analyst Ratings

Majority rating from 9 analysts.
Hold

Price Targets

Average projection from 5 analysts.
48.76% upside
High $3.00
Low $1.00
$1.21
Current price
$1.80
Average price target

ACRS Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-317.39% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$9.2M
411.11%
Net income
$-29.2M
-1.02%
Profit margin
-317.39%
-80.63%

ACRS Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 14.58%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.41
-$0.42
-$0.42
-$0.41
-
Expected
-$0.45
-$0.44
-$0.45
-$0.48
-$0.34
Surprise
-7.98%
-4.06%
-6.67%
-14.58%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Aclaris Therapeutics stock

Buy or sell Aclaris Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing